- |||||||||| Clinical, Journal: Imaging of sacroiliac joints in patients with acromegaly. (Pubmed Central) - Oct 31, 2020
Sacroiliac joints are frequently affected in acromegaly and thus this disorder mimics the features of AS and SpA. Acromegaly should be kept in mind in the differential diagnosis of AS and SpA.
- |||||||||| Retrospective data, Review, Journal: Metabolic complications in acromegaly after neurosurgery: a meta-analysis. (Pubmed Central) - Oct 30, 2020
Neurosurgery improves metabolism with a significant decrease in FPG, glucose load, HbA1c, FPI, HOMA-IR, TGDs, and LDLC and increase in HDLC. The effect on FPG seems to be more related to follow-up length than to disease control.
- |||||||||| Trial completion: Acromegaly: Patient And Physician Perspectives (clinicaltrials.gov) - Oct 28, 2020
P=N/A, N=152, Completed,
The effect on FPG seems to be more related to follow-up length than to disease control. Active, not recruiting --> Completed
- |||||||||| Journal: Updates in the Medical Treatment of Pituitary Adenomas. (Pubmed Central) - Oct 24, 2020
A growing awareness regarding all mechanisms involved in both control of pituitary secretion and cellular proliferation might allow for sole medical treatment of pituitary adenomas, especially macroadenomas, rather than surgery and/or radiation therapy, in the future. Moreover, the underlying decision on how to treat patients with pituitary adenomas should be individualized on a case-by-case basis with not only a goal of tumor shrinkage and biochemical control, but also of improving patients' quality of life.
- |||||||||| Clinical, Journal: Increased serum nesfatin-1 levels in patients with acromegaly. (Pubmed Central) - Oct 23, 2020
There was no relationship between serum nesfatin-1 levels and tumor's size, Ki-67 index, mutant p53, or MGMT proteins. However, increased serum GH levels were positively correlated with tumors' size (P = .023) and mutant p53 proteins expression (P = .028).Circulating nesfatin-1 was increased in acromegaly, which was involved in metabolism regulation.
- |||||||||| Journal: Drugs affecting obstructive sleep apnea syndrome (Pubmed Central) - Oct 23, 2020
Finally, the effect of a number of drugs on OSA is not definitively established and requires further study (benzodiazepine receptor agonist hypnotics, angiotensin-converting enzyme inhibitors, opiate receptor antagonists, antidepressants, proton-pump inhibitors, TNF-α antagonists, glutamate receptor antagonists, drugs for the treatment of acromegaly, drugs for the treatment of narcolepsy). Raising awareness of doctors of different specialties about the impact of various drugs on OSA can not only prevent the deterioration of respiratory distress during sleep, but also, with a rational individual approach, makes it possible to even improve the quality of sleep and blood saturation, thereby contributing to a more favorable course of OSA and the underlying disease.
- |||||||||| Mycapssa (octreotide) / Chiesi
Trial completion date: OPTIMAL: Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly (clinicaltrials.gov) - Oct 19, 2020
P3, N=56, Active, not recruiting,
Raising awareness of doctors of different specialties about the impact of various drugs on OSA can not only prevent the deterioration of respiratory distress during sleep, but also, with a rational individual approach, makes it possible to even improve the quality of sleep and blood saturation, thereby contributing to a more favorable course of OSA and the underlying disease. Trial completion date: May 2020 --> May 2022
- |||||||||| Clinical, Journal: Acromegaly and the information gap: patient perceptions of the journey from primary to tertiary care. (Pubmed Central) - Oct 15, 2020
Acromegalic patients have a strong need for information at the point of initial diagnosis, in particular online resources and interaction with other experienced patients. Wider dissemination of patient educational resources into primary and secondary care settings may improve overall patient satisfaction, treatment adherence and subsequent health care provider-patient relationships.
- |||||||||| [VIRTUAL] A Rare Combination of Transcription Factors in a Monomorphous Pituitary Adenoma () - Oct 13, 2020 - Abstract #CAP2020CAP_684;
This immunohistochemical positive combination is unusual, with no clinical data on this specific transcription factor expression, leaving no clinical evidence to extrapolate prognosis. To our knowledge, this is the first case in which the pituitary adenoma cells carry both PIT-1 and SF-1 transcription factors and produce both growth hormone and luteinizing hormone.
- |||||||||| [VIRTUAL] Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1076;
After RT, the level of GH decreased in this way: not suppressed only in one patient and was 22.1±0.89mMе/l, in 3patients the level of GH was suppressed, but not up to the norm and amounted to6.7±0.7mMe/l, only 7patients were suppressed and amounted to 2.46±2.2mMe/l. In all age periods, even in the period of the most activity pituitary adenoma-at the age of 26-44 years, RT is a rather effective method of treatment and gives positive results in most cases.
- |||||||||| [VIRTUAL] Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_710;
After RT, the level of GH decreased in this way: not suppressed only in one patient and was 22.1±0.89mMе/l, in 3patients the level of GH was suppressed, but not up to the norm and amounted to6.7±0.7mMe/l, only 7patients were suppressed and amounted to 2.46±2.2mMe/l. In all age periods, even in the period of the most activity pituitary adenoma-at the age of 26-44 years, RT is a rather effective method of treatment and gives positive results in most cases.
- |||||||||| Somavert (pegvisomant) / Pfizer
Trial completion date, Trial primary completion date: Acromegaly Combination Treatment Study (clinicaltrials.gov) - Sep 30, 2020
P=N/A, N=51, Recruiting,
Efforts to increase physician's awareness of acromegaly and to improve disease control are underway. Trial completion date: Mar 2020 --> Jun 2022 | Trial primary completion date: Mar 2020 --> Dec 2021
- |||||||||| Enrollment open: Effects of Mindfulness Therapy in Patients With Acromegaly and Cushing (clinicaltrials.gov) - Sep 29, 2020
P=N/A, N=120, Recruiting,
The fact that either ends of the spectrum of growth hormone (excess or deficiency) can be associated with diabetes mellitus is unique and clinicians should especially recognize that impaired glucose tolerance and even diabetes mellitus may develop in individuals predisposed to having growth hormone deficiency. Not yet recruiting --> Recruiting
- |||||||||| Journal: Pituitary microadenomas - current diagnostic and treatment methods (Pubmed Central) - Sep 26, 2020
Follow-up is advisable for endocrine-inactive microadenoma (microincidentaloma). Modern data on the incidence, clinical and endocrine features, diagnosis and treatment of various pituitary microadenomas are discussed in the article.
- |||||||||| Clinical, Journal: Parotid Gland Enlargement in Acromegaly: A Case Report of This Rare Finding. (Pubmed Central) - Sep 21, 2020
Unilateral parotid gland enlargement was also present. Our investigation showed that the parotid gland swelling was non-neoplastic and part of the organomegalic complex associated with acromegaly. Parotidomegaly represents a very rare finding in acromegaly.
- |||||||||| Oclaiz (octreotide subcutaneous depot) / Camurus
Trial completion date, Trial initiation date, Trial primary completion date: A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) - Sep 17, 2020
P3, N=140, Recruiting,
Our investigation showed that the parotid gland swelling was non-neoplastic and part of the organomegalic complex associated with acromegaly. Parotidomegaly represents a very rare finding in acromegaly. Trial completion date: Sep 2021 --> Apr 2022 | Initiation date: Jul 2020 --> Oct 2019 | Trial primary completion date: Aug 2021 --> Mar 2022
- |||||||||| octreotide subcutaneous depot (CAM2029) / Camurus
Trial completion date, Trial primary completion date: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) - Sep 17, 2020
P3, N=78, Recruiting,
Trial completion date: Sep 2021 --> Apr 2022 | Initiation date: Jul 2020 --> Oct 2019 | Trial primary completion date: Aug 2021 --> Mar 2022 Trial completion date: Feb 2021 --> Oct 2021 | Trial primary completion date: Jan 2021 --> Sep 2021
- |||||||||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal: Gestational diabetes and Acromegaly: single centre experience of 14 pregnancies. (Pubmed Central) - Sep 16, 2020
The prevalence of GD in our women is higher than that reported in the literature, probably resulting from the systematic GD screening and to the age of women. Therefore, routine screening of GD should be considered in women with acromegaly, particularly in those with risk factors of GD and with uncontrolled IGF-1 levels before pregnancy.
- |||||||||| Clinical, Review, Journal: Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population? (Pubmed Central) - Sep 8, 2020
The literature on an association between acromegaly and cancer is particularly abundant on either colorectal cancer or thyroid cancer, and an endless debate is ongoing whether patients with acromegaly should be submitted to specific oncology screening and surveillance protocols. The aim of the present work is to review the more most recent data on the risk of either colorectal cancer or thyroid cancer in acromegaly and discuss the opportunity for specific screening in relation to the accepted procedures in the general population.
- |||||||||| Clinical, Journal: The partner's perspective of the impact of pituitary disease: Looking beyond the patient. (Pubmed Central) - Sep 2, 2020
Partners mentioned worries related to the pituitary disease and negative beliefs about medication, coping challenges, relationship issues, social issues and unmet needs regarding care. This study emphasizes the importance of not only paying attention to psychosocial well-being of people with pituitary disease but also to their partners.
|
